Category Archives: Patently BIOtech

Join us for the IP Symposium at the 2016 BIO World Congress!

World Congress-BIOFacebook_12000x1200

Ah, San Diego. What is it they say about you? Come for the beaches…. Stay for the fish tacos. Here at BIO, we’ll admit it—San Diego, you have enticed us with your perpetual 65° temperatures. And it’s the perfect time to join BIO and the 1,200 attendees from 50 countries at the 2016 BIO World Congress, the world’s largest industrial biotechnology event! But wait…THERE’S MORE? We couldn’t be more excited to announce that BIO will Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

What We’ll Be Talking about at the BIO Spring IPCC Conference


It’s time once again for BIO’s Spring IPCC Conference! BIO’s biannual Intellectual Property Counsels Committee Conference provides informative and interesting educational sessions on what’s happening in the biotech IP sector. It also provides a chance to network with industry colleagues, promoting discussion and fostering new and exciting relationships. Attendees represent all swaths of the biotech sector, including pharma companies, law firms, academia and government, coming together from the U.S. and abroad to attend this one Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , ,

“II Ca-Be-lly, or Not II Ca-Be-lly?”: Is The Famous Cabilly II Antibody Patent Near Extinction?


Guest post by Konstantin Linnik, Ph.D., Isaac Hubner, Ph.D, and Lana Gladstein, who are attorneys in the Boston office of Nutter McClennen & Fish LLP. On February 5, 2016, the Patent Trial and Appeal Board (“PTAB”) issued a decision to institute an Inter Partes Review (“IPR”) of Genentech’s “Cabilly II” patent (U.S. Patent No. 6,331,415). This triggered the one-month deadline for third parties to request joinder under 37 CFR § 42.122(b).  Whether you are a licensee, or otherwise Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Patently Biotech’s Top Articles of 2015

Intellectual property and patent reform have dominated headlines in 2015. As we close out the year, let’s take a look at some of this year’s most memorable Patently BIOtech coverage. Here are Patently Biotech’s top blog posts of 2015: This Independence Day, Let’s Thank the Inventors IP Sessions at BIO 2015: The Impact of the Inter Partes Review on (BIO)Pharma FDA Acts on Biosimilars Seventy Nine House Members Express Concern with H.R. 9 Make sure Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post

Patent Reform in the News

© 2010 Opensourceway (CC 2.0 Attribution ShareAlike) (

The New York Post and The Washington Post have both run Op-eds in the last week addressing the need to reform the PTO’s inter partes review (IPR) process within current patent reform legislative efforts. Both opinions point to the weakness within the IPR process exposed by short selling practices of predatory hedge fund managers. Click on the links below to read more: From the New York Post: Hedge-fund investors are coming to raid your medicine cabinet. By Peter Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,